Although PD-1/PD-L1 inhibitors have demonstrated significant clinical efficacy in the treatment of RCC, the research landscape surrounding these immune checkpoint targets has not yet been systematically mapped using bibliometric approaches. This evidence concerns the gene PDCD1 and renal cell carcinoma.